NASDAQ:ARCT
Arcturus Therapeutics Holdings Inc. Stock News
$29.78
-0.720 (-2.36%)
At Close: May 17, 2024
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
04:01pm, Wednesday, 15'th May 2024
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the deve
Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out for
11:05am, Wednesday, 01'st May 2024
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
04:01pm, Thursday, 25'th Apr 2024
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the deve
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2023 Earnings Call Transcript
06:32pm, Thursday, 07'th Mar 2024
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations, Public R
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
06:11pm, Thursday, 07'th Mar 2024
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $1.69. This compares to earnings of $4.33 per share a year ago.
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
04:01pm, Thursday, 07'th Mar 2024
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the deve
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
02:26pm, Monday, 04'th Mar 2024
Arcturus' (ARCT) steady progress with its product candidate, ARCT-032, for the treatment of cystic fibrosis is encouraging.
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
03:20pm, Monday, 26'th Feb 2024
While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
09:00am, Monday, 26'th Feb 2024
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
01:04pm, Wednesday, 21'st Feb 2024
Biotech stocks are often at the forefront of innovation. These are the companies we hear about that are driving breakthroughs in healthcare.
3 Tech Stocks That Could Be Multibaggers in the Making: February Edition
04:39pm, Tuesday, 20'th Feb 2024
We've all heard the story with AI by now, and for good reason. It has massive potential to overhaul almost every aspect of our lives.
Study conducted by Meiji Seika Pharma in Japan Short communication follows previously published data in The Lancet Infectious Diseases demonstrating Immunological Non-Inferiority to Wuhan Strain a
Why Arcturus Therapeutics Has A Promising Future With Innovative CF And COVID Treatments
11:25am, Friday, 02'nd Feb 2024
Arcturus Therapeutics is a biotechnology company specializing in rare and infectious diseases, with approved COVID and influenza vaccines in Japan and the EU. The company is developing game-changing t
Arcturus: H1 2024 Rare Disease Drug Data On Deck
05:20pm, Wednesday, 31'st Jan 2024
Arcturus Therapeutics Holdings Inc. interim results from the phase 1b study, using ARCT-032 for the treatment of patients with Cystic Fibrosis, are expected in the 1st half of 2024. The global Cystic